Asthma

Antisense ERK-1 Suggested As Gene Therapy For Hyperplasia

Published in Gene Therapy Weekly, June 7th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - Controlling extracellular signal-regulated kinases may lead to new therapy preventing smooth muscle cell proliferation in the airways of patients with asthma, new research suggests.

J.H. Lee and colleagues in the Department of Pharmacology at Sydney University in Australia are focusing on the mechanisms behind increased smooth muscle mass seen in asthmatic airways. They explained that extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) belong to a family of kinases that are mitogen-activated proteins (MAP kinases). MAP kinases, which are enzymes that transfer phosphates from ADP or ATP to target molecules,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-06-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry